Home >> Healthcare >> Food & Beverage >>

Systemic Lupus Erythematosus - Pipeline Review, H2 2015

Published: Aug-2015 | Format: PDF | Global Markets Direct | Number of pages: 301 | Code: MRS - 35132

Systemic Lupus Erythematosus - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Systemic Lupus Erythematosus - Pipeline Review, H2 2015’, provides an overview of the Systemic Lupus Erythematosus’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Systemic Lupus Erythematosus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Systemic Lupus Erythematosus and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Systemic Lupus Erythematosus
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Systemic Lupus Erythematosus and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Systemic Lupus Erythematosus products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Systemic Lupus Erythematosus pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Systemic Lupus Erythematosus
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Systemic Lupus Erythematosus pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Systemic Lupus Erythematosus Overview 11
Therapeutics Development 12
Pipeline Products for Systemic Lupus Erythematosus - Overview 12
Pipeline Products for Systemic Lupus Erythematosus - Comparative Analysis 13
Systemic Lupus Erythematosus - Therapeutics under Development by Companies 14
Systemic Lupus Erythematosus - Therapeutics under Investigation by Universities/Institutes 19
Systemic Lupus Erythematosus - Pipeline Products Glance 20
Late Stage Products 20
Clinical Stage Products 21
Early Stage Products 22
Systemic Lupus Erythematosus - Products under Development by Companies 23
Systemic Lupus Erythematosus - Products under Investigation by Universities/Institutes 28
Systemic Lupus Erythematosus - Companies Involved in Therapeutics Development 29
4SC AG 29
AbbVie Inc. 30
Ablynx NV 31
Actelion Ltd 32
AiCuris GmbH & Co. KG 33
Amgen Inc. 34
Anthera Pharmaceuticals‚ Inc. 35
Argos Therapeutics, Inc. 36
Biogen, Inc. 37
Biotest AG 38
Bristol-Myers Squibb Company 39
Celgene Corporation 40
Cellular Biomedicine Group, Inc. 41
Chong Kun Dang Pharmaceutical Corp. 42
Eisai Co., Ltd. 43
F. Hoffmann-La Roche Ltd. 44
Genosco 45
Genovax S.r.l. 46
GlaxoSmithKline Plc 47
Hansa Medical AB 48
ImmuNext, Inc. 49
Immunomedics, Inc. 50
Immupharma Plc 51
Invion Limited 52
Johnson & Johnson 53
Kadmon Corporation, LLC 54
Karyopharm Therapeutics, Inc. 55
Kineta, Inc. 56
Lead Discovery Center GmbH 57
MacroGenics, Inc. 58
MedAnnex Ltd 59
MedImmune, LLC 60
Medsenic 61
Merck KGaA 62
Mitsubishi Tanabe Pharma Corporation 63
Neovacs SA 64
Nippon Chemiphar Co., Ltd. 65
Ocata Therapeutics, Inc. 66
Padlock Therapeutics, Inc. 67
Pfizer Inc. 68
Plexxikon Inc. 69
Principia Biopharma Inc. 70
RedHill Biopharma Ltd. 71
Redx Pharma Plc 72
Resolve Therapeutics, LLC 73
Sanofi 74
Sarepta Therapeutics, Inc. 75
SBI Biotech Co., Ltd. 76
Seattle Genetics, Inc. 77
Takeda Pharmaceutical Company Limited 78
Therapix Biosciences Ltd 79
UCB S.A. 80
Xencor, Inc. 81
XTL Biopharmaceuticals Ltd. 82
Systemic Lupus Erythematosus - Therapeutics Assessment 83
Assessment by Monotherapy Products 83
Assessment by Combination Products 84
Assessment by Target 85
Assessment by Mechanism of Action 88
Assessment by Route of Administration 91
Assessment by Molecule Type 93
Drug Profiles 95
(rifabutin + clarithromycin + clofazimine) - Drug Profile 95
abatacept - Drug Profile 98
ABBV-084 - Drug Profile 101
ABS-11 - Drug Profile 102
ACT-334441 - Drug Profile 103
AGS-009 - Drug Profile 104
AIC-284 - Drug Profile 105
ALX-0061 - Drug Profile 106
AMG-557 - Drug Profile 108
AMG-729 - Drug Profile 110
AMG-811 - Drug Profile 111
anifrolumab - Drug Profile 112
Annexuzlimab - Drug Profile 114
Antibody to Inhibit ILT7 for Systemic Lupus Erythematosus - Drug Profile 115
Antisense Oligonucleotide to Inhibit TLRs for Systemic Lupus Erythematosus and Graft Versus Host Disease - Drug Profile 116
arsenic trioxide - Drug Profile 117
AT-791 - Drug Profile 118
atacicept - Drug Profile 119
BB-004 - Drug Profile 121
belimumab - Drug Profile 122
BIIB-059 - Drug Profile 125
blisibimod - Drug Profile 126
brentuximab vedotin - Drug Profile 129
BT-063 - Drug Profile 135
CC-220 - Drug Profile 136
Cell Therapy for Autoimmune Diseases and GVHD - Drug Profile 138
CKD-506 - Drug Profile 140
dalazatide - Drug Profile 141
dapirolizumab pegol - Drug Profile 143
Drug to Inhibit PAD for Autoimmune Diseases, CNS and Oncology - Drug Profile 145
E-6446 - Drug Profile 147
edratide - Drug Profile 148
Endoglycosidase of Streptococcus pyogenes - Drug Profile 149
forigerimod acetate - Drug Profile 150
GNKS-356 - Drug Profile 152
GX-101 - Drug Profile 153
IGM-001 - Drug Profile 154
IMP-10 - Drug Profile 155
INV-103 - Drug Profile 156
JB-6121 - Drug Profile 158
KD-025 - Drug Profile 159
KPT-350 - Drug Profile 161
Leukothera - Drug Profile 162
lulizumab pegol - Drug Profile 164
MGD-010 - Drug Profile 165
milatuzumab - Drug Profile 167
Monoclonal Antibody to Inhibit CD3 for Autoimmune Disorders, CNS Disorders, Infectious Diseases, Liver Diseases, Metabolic Disorders and Cardiovascular Diseases - Drug Profile 169
MT-1303 - Drug Profile 171
NC-2400 - Drug Profile 172
NCS-613 - Drug Profile 173
PF-04236921 - Drug Profile 174
PRN-1008 - Drug Profile 175
Recombinant Proteins for Systemic Lupus Erythematosus - Drug Profile 176
RN-486 - Drug Profile 177
RO-5461111 - Drug Profile 178
RSLV-132 - Drug Profile 179
RSLV-133 - Drug Profile 180
SAR-113244 - Drug Profile 181
SBI-3150 - Drug Profile 182
sifalimumab - Drug Profile 183
SM-101 - Drug Profile 185
SM-934 - Drug Profile 188
Small Molecule to Inhibit BTK for Cancer and Autoimmune disorders - Drug Profile 189
Small Molecule to Inhibit Immunoproteasome Subunit LMP7 for Autoimmune Disorders and Viral Infections - Drug Profile 190
Small Molecule to Inhibit NFkB for Ophthalmology, Oncology and Immunology - Drug Profile 191
Small Molecule to Inhibit RORgammat for CNS, Autoimmune and Gastrointestinal Disorders - Drug Profile 193
Small Molecule to Inhibit SYK for Systemic Lupus Erythematosus and Rheumatoid Arthritis - Drug Profile 194
Small Molecules to Inhibit FMS Kinase for Immunology, Gastrointestinal, Respiratory and Central Nervous Sytem Diseases - Drug Profile 195
Small Molecules to Inhibit NET Formation for Sepsis and SLE - Drug Profile 196
Stem Cell Therapy for Autoimmune Diseases - Drug Profile 197
Stem Cell Therapy for Cerebral Palsy and Systemic Lupus Erythematosus - Drug Profile 198
Stem Cell Therapy for Systemic Lupus Erythematosus - Drug Profile 199
Synthetic Peptide for Systemic Lupus Erythematosus - Drug Profile 200
Synthetic Peptides for Systemic Lupus Erythematosus - Drug Profile 201
TAK-079 - Drug Profile 202
TAK-114 - Drug Profile 203
TAM-01 - Drug Profile 205
ustekinumab - Drug Profile 206
Vaccine for Systemic Lupus Erythematosus - Drug Profile 209
Vaccine to Target Interferon Alpha for Systemic Lupus Erythematosus, Chronic Viral Infections and Dermatomyositis - Drug Profile 210
venetoclax - Drug Profile 213
VISTA-Ig - Drug Profile 216
XmAb-5871 - Drug Profile 217
Y-27 - Drug Profile 218
Systemic Lupus Erythematosus - Recent Pipeline Updates 219
Systemic Lupus Erythematosus - Dormant Projects 279
Systemic Lupus Erythematosus - Discontinued Products 284
Systemic Lupus Erythematosus - Product Development Milestones 285
Featured News & Press Releases 285
Appendix 294
Methodology 294
Coverage 294
Secondary Research 294
Primary Research 294
Expert Panel Validation 294
Contact Us 294
Disclaimer 295

List of Tables
Number of Products under Development for Systemic Lupus Erythematosus, H2 2015 18
Number of Products under Development for Systemic Lupus Erythematosus - Comparative Analysis, H2 2015 19
Number of Products under Development by Companies, H2 2015 21
Number of Products under Development by Companies, H2 2015 (Contd..1) 22
Number of Products under Development by Companies, H2 2015 (Contd..2) 23
Number of Products under Development by Companies, H2 2015 (Contd..3) 24
Number of Products under Investigation by Universities/Institutes, H2 2015 25
Comparative Analysis by Late Stage Development, H2 2015 26
Comparative Analysis by Clinical Stage Development, H2 2015 27
Comparative Analysis by Early Stage Development, H2 2015 28
Products under Development by Companies, H2 2015 29
Products under Development by Companies, H2 2015 (Contd..1) 30
Products under Development by Companies, H2 2015 (Contd..2) 31
Products under Development by Companies, H2 2015 (Contd..3) 32
Products under Development by Companies, H2 2015 (Contd..4) 33
Products under Investigation by Universities/Institutes, H2 2015 34
Systemic Lupus Erythematosus - Pipeline by 4SC AG, H2 2015 35
Systemic Lupus Erythematosus - Pipeline by AbbVie Inc., H2 2015 36
Systemic Lupus Erythematosus - Pipeline by Ablynx NV, H2 2015 37
Systemic Lupus Erythematosus - Pipeline by Actelion Ltd, H2 2015 38
Systemic Lupus Erythematosus - Pipeline by AiCuris GmbH & Co. KG, H2 2015 39
Systemic Lupus Erythematosus - Pipeline by Amgen Inc., H2 2015 40
Systemic Lupus Erythematosus - Pipeline by Anthera Pharmaceuticals‚ Inc., H2 2015 41
Systemic Lupus Erythematosus - Pipeline by Argos Therapeutics, Inc., H2 2015 42
Systemic Lupus Erythematosus - Pipeline by Biogen, Inc., H2 2015 43
Systemic Lupus Erythematosus - Pipeline by Biotest AG, H2 2015 44
Systemic Lupus Erythematosus - Pipeline by Bristol-Myers Squibb Company, H2 2015 45
Systemic Lupus Erythematosus - Pipeline by Celgene Corporation, H2 2015 46
Systemic Lupus Erythematosus - Pipeline by Cellular Biomedicine Group, Inc., H2 2015 47
Systemic Lupus Erythematosus - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2015 48
Systemic Lupus Erythematosus - Pipeline by Eisai Co., Ltd., H2 2015 49
Systemic Lupus Erythematosus - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 50
Systemic Lupus Erythematosus - Pipeline by Genosco, H2 2015 51
Systemic Lupus Erythematosus - Pipeline by Genovax S.r.l., H2 2015 52
Systemic Lupus Erythematosus - Pipeline by GlaxoSmithKline Plc, H2 2015 53
Systemic Lupus Erythematosus - Pipeline by Hansa Medical AB, H2 2015 54
Systemic Lupus Erythematosus - Pipeline by ImmuNext, Inc., H2 2015 55
Systemic Lupus Erythematosus - Pipeline by Immunomedics, Inc., H2 2015 56
Systemic Lupus Erythematosus - Pipeline by Immupharma Plc, H2 2015 57
Systemic Lupus Erythematosus - Pipeline by Invion Limited, H2 2015 58
Systemic Lupus Erythematosus - Pipeline by Johnson & Johnson, H2 2015 59
Systemic Lupus Erythematosus - Pipeline by Kadmon Corporation, LLC, H2 2015 60
Systemic Lupus Erythematosus - Pipeline by Karyopharm Therapeutics, Inc., H2 2015 61
Systemic Lupus Erythematosus - Pipeline by Kineta, Inc., H2 2015 62
Systemic Lupus Erythematosus - Pipeline by Lead Discovery Center GmbH, H2 2015 63
Systemic Lupus Erythematosus - Pipeline by MacroGenics, Inc., H2 2015 64
Systemic Lupus Erythematosus - Pipeline by MedAnnex Ltd, H2 2015 65
Systemic Lupus Erythematosus - Pipeline by MedImmune, LLC, H2 2015 66
Systemic Lupus Erythematosus - Pipeline by Medsenic, H2 2015 67
Systemic Lupus Erythematosus - Pipeline by Merck KGaA, H2 2015 68
Systemic Lupus Erythematosus - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2015 69
Systemic Lupus Erythematosus - Pipeline by Neovacs SA, H2 2015 70
Systemic Lupus Erythematosus - Pipeline by Nippon Chemiphar Co., Ltd., H2 2015 71
Systemic Lupus Erythematosus - Pipeline by Ocata Therapeutics, Inc., H2 2015 72
Systemic Lupus Erythematosus - Pipeline by Padlock Therapeutics, Inc., H2 2015 73
Systemic Lupus Erythematosus - Pipeline by Pfizer Inc., H2 2015 74
Systemic Lupus Erythematosus - Pipeline by Plexxikon Inc., H2 2015 75
Systemic Lupus Erythematosus - Pipeline by Principia Biopharma Inc., H2 2015 76
Systemic Lupus Erythematosus - Pipeline by RedHill Biopharma Ltd., H2 2015 77
Systemic Lupus Erythematosus - Pipeline by Redx Pharma Plc, H2 2015 78
Systemic Lupus Erythematosus - Pipeline by Resolve Therapeutics, LLC, H2 2015 79
Systemic Lupus Erythematosus - Pipeline by Sanofi, H2 2015 80
Systemic Lupus Erythematosus - Pipeline by Sarepta Therapeutics, Inc., H2 2015 81
Systemic Lupus Erythematosus - Pipeline by SBI Biotech Co., Ltd., H2 2015 82
Systemic Lupus Erythematosus - Pipeline by Seattle Genetics, Inc., H2 2015 83
Systemic Lupus Erythematosus - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015 84
Systemic Lupus Erythematosus - Pipeline by Therapix Biosciences Ltd, H2 2015 85
Systemic Lupus Erythematosus - Pipeline by UCB S.A., H2 2015 86
Systemic Lupus Erythematosus - Pipeline by Xencor, Inc., H2 2015 87
Systemic Lupus Erythematosus - Pipeline by XTL Biopharmaceuticals Ltd., H2 2015 88
Assessment by Monotherapy Products, H2 2015 89
Assessment by Combination Products, H2 2015 90
Number of Products by Stage and Target, H2 2015 92
Number of Products by Stage and Mechanism of Action, H2 2015 95
Number of Products by Stage and Route of Administration, H2 2015 98
Number of Products by Stage and Molecule Type, H2 2015 100
Systemic Lupus Erythematosus Therapeutics - Recent Pipeline Updates, H2 2015 225
Systemic Lupus Erythematosus - Dormant Projects, H2 2015 285
Systemic Lupus Erythematosus - Dormant Projects (Contd..1), H2 2015 286
Systemic Lupus Erythematosus - Dormant Projects (Contd..2), H2 2015 287
Systemic Lupus Erythematosus - Dormant Projects (Contd..3), H2 2015 288
Systemic Lupus Erythematosus - Dormant Projects (Contd..4), H2 2015 289
Systemic Lupus Erythematosus - Discontinued Products, H2 2015 290

List of Figures
Number of Products under Development for Systemic Lupus Erythematosus, H2 2015 18
Number of Products under Development for Systemic Lupus Erythematosus - Comparative Analysis, H2 2015 19
Number of Products under Development by Companies, H2 2015 20
Number of Products under Investigation by Universities/Institutes, H2 2015 25
Comparative Analysis by Clinical Stage Development, H2 2015 27
Comparative Analysis by Early Stage Products, H2 2015 28
Assessment by Monotherapy Products, H2 2015 89
Number of Products by Top 10 Targets, H2 2015 91
Number of Products by Stage and Top 10 Targets, H2 2015 91
Number of Products by Top 10 Mechanism of Actions, H2 2015 94
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 94
Number of Products by Routes of Administration, H2 2015 97
Number of Products by Stage and Routes of Administration, H2 2015 97
Number of Products by Top 10 Molecule Types, H2 2015 99
Number of Products by Stage and Top 10 Molecule Types, H2 2015 99

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

Single User | $(USD)2000 View Pricing